Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients: A 12-month, Single Center, Randomized, Open-label Study of Efficacy Comparing Immediate Treatment With and Without Thymoglobulin® 1.5 mg/kg/d for 5 Consecutive Days in Heart Transplant Recipients

Trial Profile

A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients: A 12-month, Single Center, Randomized, Open-label Study of Efficacy Comparing Immediate Treatment With and Without Thymoglobulin® 1.5 mg/kg/d for 5 Consecutive Days in Heart Transplant Recipients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Methylprednisolone; Mycophenolate mofetil; Prednisone; Sirolimus; Tacrolimus
  • Indications Heart transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2018 Planned End Date changed from 1 Oct 2019 to 31 Mar 2021.
    • 10 Oct 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.
    • 10 Oct 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top